Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Endoscopy Devices Market Analysis

The endoscopy devices market stands at USD 40.10 billion in 2025 and is forecast to reach roughly USD 55.09 billion by 2030, reflecting a compound annual growth rate (CAGR) close to 6.56%. Rising acceptance of minimally invasive surgery continues to reshape hospital capital budgets, drawing investment toward visualization towers and advanced imaging modules that shorten patient recovery times while freeing operating-room slots for high-margin procedures. At the same time, infection-control mandates are redirecting procurement toward disposable or partly disposable scopes, a shift that not only reduces reprocessing labor but also limits reimbursement penalties linked to hospital-acquired infections. Growth in Asia-Pacific is outpacing global averages as expanding insurance coverage collides with a shortage of trained endoscopists, prompting buyers in that region to favor intuitive, software-guided platforms that compress learning curves. Established North American providers remain anchor customers, yet their quick adoption of single-use duodenoscopes is pressuring manufacturers to balance premium pricing with volume-driven cost efficiencies.

Global Endoscopy Devices Market Trends and Insights

Widespread Shift Toward Minimally Invasive Procedures Across Surgical Specialties

Across specialties, clinicians are reshaping care pathways around minimally invasive interventions. Endoluminal robotics—allowing navigation through natural orifices—illustrates how product roadmaps are converging on the same value proposition: lower patient trauma, shorter admissions, and quicker recoveries. A second-order implication is that hospitals now tie capital-budget requests for imaging suites and OR renovations to claims of throughput gains driven by these technologies; therefore, endoscopy vendors must increasingly compete on measurable workflow efficiencies rather than image quality alone.

Continuous Innovation in Endoscopy Visualization Enhancing Clinical Outcomes

High-definition optics, 3D imagery, and software-enhanced contrast platforms have improved early-lesion detection. Olympus’s EVIS EXERA III, for example, leverages Narrow Band Imaging (NBI) and Dual Focus to lift adenoma detection rates during colonoscopy. The strategic corollary for providers is the emerging ability to selectively biopsy smaller tissue volumes, which not only accelerates pathology turnaround but also reduces consumable costs at scale. That optimization, in turn, allows outpatient facilities to maintain competitive reimbursement rates while still meeting quality benchmarks.

Global Shortage of Trained Endoscopists and Support Staff

Expanding indications have outpaced the global supply of skilled endoscopists. The American Society for Gastrointestinal Endoscopy stresses that advanced procedures such as ERCP and EUS require prolonged mentorships, deterring rapid credentialing. A pragmatic consequence for suppliers is an emerging market for systems with integrated guidance software, standard-of-care checklists, and artificial-intelligence-assisted navigation. Devices that shorten training timelines improve utilization rates, thereby strengthening the business case for administrators deciding between competing capital requests.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Reimbursement & Public-Health Programs Supporting Preventive Endoscopy
2. Rising Global Incidence of Gastrointestinal & Colorectal Cancers Driving Screening Demand
3. Persistent Infection-Control Challenges and Heightened Regulatory Scrutiny

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Gastrointestinal endoscopy secured 54.9% market share in 2024, reflecting heavy reliance on colonoscopy and upper-GI diagnostics. Yet laparoscopy is projected to rise at an 8.9% CAGR through 2030, driven by expanded indications such as bariatric revisions and endometriosis treatment. This momentum suggests that multi-disciplinary OR teams may push for modular tower configurations capable of switching between laparoscopic and endoscopic modes, effectively bifurcating procurement strategies into high-volume GI suites versus flexible multi-specialty rooms.

Endoscopic ultrasound (EUS) is also gaining traction, evidenced by rising upper-GI EUS volumes in the United States. Because EUS facilitates both staging and therapeutic interventions like celiac plexus neurolysis, hospitals have started to position the technology as a revenue-enhancing adjunct rather than a diagnostic cost center, subtly shifting budgeting authority from radiology to GI departments.

Reusable scopes still dominate with an 82% share in 2024, but disposables are growing 12.5% annually. Studies comparing disposable-sheath gastroscopes with standard devices demonstrate reprocessing times dropping from roughly 48 minutes to under 10 minutes, effectively tripling possible daily throughput. That throughput improvement is compelling when one considers that most ASCs operate on tight daily schedules; an extra two to three cases per room can materially improve EBITDA margins without extending clinic hours.

The knock-on effect is a heightened focus on waste management and sustainability, as facility managers weigh infection risk mitigation against environmental impact. This dual consideration is likely to influence future purchasing criteria toward recyclable materials and take-back programs, introducing new service-line revenue models for manufacturers.

The Endoscopy Devices Market Report is Segmented by Device Type (Endoscopes [Rigid Endoscopes, and More], Endoscopic Operative Devices [Access Devices, and More], and More), Application (Gastrointestinal, and More), Usability (Reprocessed / Reusable Devices, and More), End-User (Hospitals, Academic Medical Centers, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Olympus
2. Boston Scientific
3. Medtronic
4. FUJIFILM
5. Karl Storz
6. Stryker
7. Johnson & Johnson (Ethicon Endo-Surgery)
8. HOYA
9. Conmed
10. Richard Wolf
11. Cook Group
12. Smiths Group
13. Intuitive Surgical
14. Ambu
15. Arthrex
16. B. Braun
17. Ackermann Instrumente
18. STERIS
19. Interscope Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support